Navigation Links
Lung cancer study hints at new treatments
Date:7/9/2014

Studying the most common type of lung cancer, researchers have uncovered mutations in a cell-signaling pathway that plays a role in forming tumors. The new knowledge may expand treatments for patients because drugs targeting some of these genetic changes already are available or are in clinical trials.

Reporting July 9 in Nature, investigators from The Cancer Genome Atlas (TCGA), including researchers at Washington University School of Medicine in St. Louis, Harvard Medical School and other institutions, studied tumors from 230 patients with lung adenocarcinoma.

"This is the first time we have had a panoramic look at the genomic landscape of this many lung tumor specimens," said oncologist Ramaswamy Govindan, MD, professor of medicine at Washington University and TCGA lung cancer project co-chair. "These studies reinforce the opinion that lung cancer is a very heterogeneous disease."

Combined with an earlier study of 178 patients with lung squamous cell carcinoma, TCGA researchers now have published genetic data on about 400 lung cancer patients and are working to analyze tumors from 600 more. The investigators included scientists at The Genome Institute at Washington University and other major sequencing centers.

In the new study, among the myriad genetic changes observed in adenocarcinoma, one cell-signaling pathway stood out. About 75 percent of the samples had mutations that overactivated a pathway called RTK/RAS/RAF, known for roles in tumor growth.

"It is remarkable how important the RTK/RAS/RAF pathway appears to be," said Govindan, who treats patients at Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine. "Mutations in this particular pathway promote cancer cell proliferation. What is amazing is how many ways this pathway can be activated.

"We also know these tumors are not static," he added. "They evolve. We have to be looking at multiple biopsies over time to see how the tumor cells escape, inhibiting one pathway and becoming resistant to therapies."

The researchers also found other relevant mutations in important genes such as EGFR, NF1, NF2 and MET. Such findings could be valuable to a clinical trial known as ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial) that Govindan is leading. The trial will involve the screening of tumors from several thousand lung cancer patients for alterations in genes called EGFR and ALK. After surgery to remove their tumors, these patients will be invited to participate in clinical trials studying drugs targeting these dysfunctional genes.

The ALCHEMIST trial builds on the current study and also potentially will provide additional tumor samples for genomic analysis. A large sample size is important in accurately identifying mutations driving lung tumor growth.

"Patients with lung cancer often have substantial tobacco exposure, which leads to a lot of mutations," Govindan said. "We may not be able to find significant mutations unless we study multiple samples from several thousand patients."

Despite such progress in understanding lung cancer the most common cause of cancer deaths worldwide the investigators emphasize that the best way to reduce lung cancer deaths is to help people stop smoking and encourage others to never start.


'/>"/>

Contact: Julia Evangelou Strait
straitj@wustl.edu
314-286-0141
Washington University School of Medicine
Source:Eurekalert

Related medicine news :

1. Fox Chase researchers recommend updating the staging criteria for breast cancer diagnoses
2. MyChart use skyrocketing among cancer patients, UT Southwestern study finds
3. A possible pathway for inhibiting liver and colon cancer is found
4. Low doses of arsenic cause cancer in male mice
5. Support team aiding caregivers of cancer patients shows success, CWRU researchers report
6. Does cycling increase risk for erectile dysfunction, infertility, or prostate cancer?
7. Concern at lack of teenage patients in cancer trials
8. NUS researchers discover novel protein complex with potential to combat gastric cancer
9. First cancer immunotherapy for dogs developed
10. Association found between high cholesterol and breast cancer
11. Upending a cancer dogma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Apple ... care services, staged a mock evacuation of the facility as part of a disaster ... Fire Department, Echo Hose EMS and Shelton City Emergency Manager, as well as the ...
(Date:10/13/2017)... , ... October 13, 2017 , ... Global Healthcare Management’s ... Alexandria Park in Milford, NJ. This free event, sponsored by Global Healthcare Management’s ... The fun run is geared towards children of all ages; it is a ...
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the ... danger possible to save lost souls in the Philippines. “The Journey: From the Mountains ... a dedicated teacher of the Bible. She has taught all ages and currently teaches ...
(Date:10/12/2017)... ... October 12, 2017 , ... Planet Fitness, one of the largest and ... plans to open a flagship location in Covington, LA at 401 N. U.S. Highway ... store next to Office Depot in the Holiday Square shopping center. Its location allows ...
(Date:10/12/2017)... ... 2017 , ... Asante, a nationally recognized health system in ... existing home health joint venture through an agreement, effective October 1, 2017, to ... home health company with Asante, delivering clinically integrated care, for the past eight ...
Breaking Medicine News(10 mins):
(Date:10/10/2017)... -- NDS received FDA 510(k) clearance in May 2017 for its highly ... designed for endoscopy environments. An innovative secondary monitor solution, ZeroWire ... support the improvement of patient outcomes, procedural efficiency, and the lowering ... ... ...
(Date:10/4/2017)... 4, 2017  South Korean-based healthcare product Development Company ... "cprCUBE" on Kickstarter. The device will educate the user ... with better efficiency compared to the dated and pricey ... on efficacy of the compression for a more informed ... goal to raise $5,000. ...
(Date:10/2/2017)... 2017  Eli Lilly and Company (NYSE: ... third quarter of 2017 on Tuesday, October 24, 2017. ... day with the investment community and media to further ... call will begin at 9 a.m. Eastern time. Investors, ... webcast of the conference call through a link that ...
Breaking Medicine Technology: